An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations

References

• NoseworthyJHLucchinettiCRodriguezMWeinshenkerBGMultiple sclerosisN Engl J Med20003431393895211006371
   PubMed Web of Science ®Google Scholar
• TullmanMJOverview of epidemiology, diagnosis, and disease progression associated with multiple sclerosisAm J Manag Care2013192 supplS15S2023544716
   PubMed Web of Science ®Google Scholar
• RenouxCVukusicSMikaeloffYAdult Neurology Departments KIDMUS Study GroupNatural history of multiple sclerosis with childhood onsetN Engl J Med2007356252603261317582070
   PubMed Web of Science ®Google Scholar
• SolaroCPonzioMMoranEThe changing face of multiple sclerosis: prevalence and incidence in an aging populationMult Scler Epub2015112
   Web of Science ®Google Scholar
• LublinFDReingoldSCDefining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple SclerosisNeurology19964649079118780061
   PubMed Web of Science ®Google Scholar
• FrischerJMBramowSDal-BiancoAThe relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain200913251175118919339255
   PubMed Web of Science ®Google Scholar
• TrojanoMPaolicelliDBellacosaACataldoSThe transition from relapsing-remitting MS to irreversible disability: clinical evaluationNeurol Sci200324suppl 5S268S27014652786
   PubMed Web of Science ®Google Scholar
• GoodinDSRederATEbersGCSurvival in MS: a randomized cohort study 21 years after the start of the pivotal IFNB-1b trialNeurology201278171315132222496198
   PubMed Web of Science ®Google Scholar
• RudickRAMillerDMHealth-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatmentCNS Drugs2008221082783918788835
   PubMed Web of Science ®Google Scholar
• MikulaPNagyovaIKrokavcovaMSocial participation and health-related qualiy of life in people with multiple sclerosisDisabil Health J201581293425130596
   PubMed Web of Science ®Google Scholar
• UccelliMMThe impact of multiple sclerosis on family members: a review of the literatureNeurodegener Dis Manag20144217718524832035
   PubMedGoogle Scholar
• SundströmPNystromLSvenningssonAFordgrenLSick leave and professional assistance for multiple sclerosis individuals in Väasterbotten County, Northern SwedenMult Scler20039551552014582779
   PubMed Web of Science ®Google Scholar
• BaumstarckKPelletierJBoucekineMAuquierPMusiQoL study group. Predictors of quality of life in patiens with relapsing-remitting multiple sclerosis: A 2-year longitudinal studyRev Neurol (Paris)2015171217318025558798
   PubMed Web of Science ®Google Scholar
• PutzkiNFischerJGottwaldK“Mensch im Mittelpunkt” Study GroupQuality of life in 1000 patients with early relapsing-remitting multiple sclerosisEur J Neurol200916671372019475754
   PubMed Web of Science ®Google Scholar
• Fernendez-JimenezEArnettPAImpact of neurological impairment, depression, cognitive function and coping on quality of life in people with multiple sclerosis: a relative importance analysisMult Scler Epub20141222
   Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease proression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol1996393898904
   Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multipl Sclerosis) Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosisLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• SorensenPSNew management algorithms in multiple sclerosisCurr Opin Neurol201427324625924759080
   PubMed Web of Science ®Google Scholar
• SormaniMPRioJTintorèMScoring treatment response in patients with relapsing multiple sclerosisMult Scler201219560561223012253
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorCWHavrdovaEAFFIRM InvestigatorsA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPASENTINEL InvestigatorsNatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med2006354991192316510745
   PubMed Web of Science ®Google Scholar
• HavrdovaEGalettaSHutchinsonMEffect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) trialLancet Neurol20098325426019201654
   PubMed Web of Science ®Google Scholar
• HavrdovaEGalettaSStefoskiDComiGFreedom from disease activity in multiple sclerosisNeurology201074suppl 3S3S720421571
   PubMed Web of Science ®Google Scholar
• Langer-GouldAAtlasSWGreenAJBollenAWPelletierDProgressive multifocal leukoencephalopathy in a patient treated with natalizumabN Engl J Med2005353437538115947078
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMastersBKTylerKLProgressive multifocal leuko-encephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Engl J Med2005353436937415947079
   PubMed Web of Science ®Google Scholar
• Van AsscheGVan RanstMSciotRProgressive multifocal leucoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med2005353436236815947080
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPFREEDOMS Study GroupA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740220089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGTRANSFORMS Study GroupOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTCONFIRM Study InvestigatorsCONFIRM Study Investigators. Placebo-controlled phase III study of oral BG-12 or glatiramer acetate in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLDEFINE Study InvestigatorsDEFINE Study Investigators. Placebo-controlled phase III study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCTEMSO Trial GroupRandomized trial of oral teriflunomide in relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• ConfavreuxCO’ConnorPComiGTOWER Trial GroupOral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled trialLancet201413324725624461574
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLCARE-MS I InvestigatorsAlemtuzumab versus interferon beta-1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLCARE-MS II InvestigatorsCARE-MS II investigatorsLancet201238098561829183923122650
   PubMed Web of Science ®Google Scholar
• BielekovaBBeckerBLMonoclonal antibodies in MS: mechanisms of actionNeurology201074suppl 1S31S4020038761
   PubMed Web of Science ®Google Scholar
• YednockTACannonCFritzLCSanchez-MadridFSteinmanLKarinNPrevention of experimental autoimmune encephalomyelitis by antibodies against alpha1beta integrinNature1992356636463661538783
   PubMed Web of Science ®Google Scholar
• TubridyNBehanPOCapildeoRThe effect of anti-alpha4 integrin antibody on brain lesion activity in MSNeurology19993346647210449105
   PubMed Web of Science ®Google Scholar
• GoodmanADRossmanHBar-OrAGLANCE InvestigatorsGLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyNeurology200972980681219255407
   PubMed Web of Science ®Google Scholar
• WoodBvan der MeiIPonsonbyALPrevalence and occurence of anxiety, depression and fatigue over time in multiple sclerosisMult Scler201219221722422729988
   PubMed Web of Science ®Google Scholar
• BakshiRShaikhZAMiletichRSFatigue in multiple sclerosis and its relationship to depression and neurologic disabilityMult Scler20006318118510871830
   PubMed Web of Science ®Google Scholar
• BergamaschiRRomaniAVersinoMPoliRCosiVClinical aspects of fatigue in multiple sclerosisFunct Neurol19971252472519439942
   PubMed Web of Science ®Google Scholar
• SvenningssonAFalkECeliusEGTynergy Trial InvestigatorsNatalizumab reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life settingPLoS One201383e5864323555589
   PubMed Web of Science ®Google Scholar
• IaffaldanoPViterboRGPaolicelliDImpact of natalizumab on cognitive performance and fatigue in relapsing multiple sclerosis: a prospective, open-label, two-year observational studyPLoS One20127435843
   Web of Science ®Google Scholar
• WickströmANyströmJSvenningssonAImproved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatmentMult Scler201319562263023012254
   PubMed Web of Science ®Google Scholar
• RudickRAMillerDHassSAFFIRM and SENTINEL InvestigatorsHealth-related quality of life in multiple sclerosis: effects of natalizumabAnn Neurol200762433534617696126
   PubMed Web of Science ®Google Scholar
• O’ConnorPGoodmanAKapposLLong-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS studyNeurology2014831788624898925
   PubMed Web of Science ®Google Scholar
• ButzkuevenHKapposLPellegriniFTYSABRI Observational Program (TOP) InvestigatorsEfficacy and safety of natalizumab in multiple sclerosis: interim observataional programme resultsJ Neurol Neurosurg Psychiatry201485111190119724532785
   PubMed Web of Science ®Google Scholar
• FerenczyMWMarshallLJNelsonCDMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC-virus induced demyelinating disease of the human brainClin Microbiol Rev201225347150622763635
   PubMed Web of Science ®Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med2012366201870188022591293
   PubMed Web of Science ®Google Scholar
• Biogen IdecBiogen Idec Medinfo2015 Available from: http://www.Tysabri.comAccessed January, 2015
   Google Scholar
• WattjesMPBarkhofFDiagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRICurr Opin Neurol201427326027024739400
   PubMed Web of Science ®Google Scholar
• FineAJSorbelloACortepeterCScarazziniLProgressive multifocal leukoencephalopathy after natalizumab discontinuationAnn Neurol201475110811524242357
   PubMed Web of Science ®Google Scholar
• DahlhausSHoepnerRChanADisease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopthy patientsJ Neurol Neurosurg Psychiatry201384101068107423606731
   PubMed Web of Science ®Google Scholar
• WenningWHaghikiaALaubenbergerJTreatment of progressive multifocal leukoencephalopathy associated with natalizumabN Engl J Med2009361111075108019741228
   PubMed Web of Science ®Google Scholar
• CliffordDBDe LucaASimpsonDMArendtGGiovannoniGNathANatalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesLancet Neurol20109443844620298967
   PubMed Web of Science ®Google Scholar
• VermerschPKapposLGoldRClinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyNeurology201176201607170421536645
   PubMed Web of Science ®Google Scholar
• Dong-SiTRichmanSWattjesMPOutcome and survival of asymptomatic PML in natalizumab-treated MS patientsAnn Clin Transl Neurol201411075576425493267
   PubMed Web of Science ®Google Scholar
• RothwellPMMcDowellZWongCKDormanPJDoctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosisBMJ19973147094158015839169401
   PubMed Web of Science ®Google Scholar
• HeesenCKleiterINguyenFRisk perception in natalizumab-treated patients and their neurologistsMult Scler201016121507151220826527
   PubMed Web of Science ®Google Scholar
• O’ConnorPWGoodmanAKapposLDisease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology201176221858186521543733
   PubMed Web of Science ®Google Scholar
• LassmannHBrückWLucchinettiCFThe immunopathology of multiple sclerosis: an overview [review]Brain Pathol200717221021817388952
   PubMed Web of Science ®Google Scholar
• SormaniMPBruzziPCan we measure long-term treatment effects in multiple sclerosis? [review]Nat Rev Neurol201511317618225534913
   PubMed Web of Science ®Google Scholar
• ScalfariANeuhausADegenhardtAThe natural history of multiple sclerosis, a geographically based study. 10. Relapses and long-term disabilityBrain201013371914192920534650
   PubMed Web of Science ®Google Scholar
• FisnikuLKBrexPAAltmannDRDisability and T2 MRI lesions: a 20-year follow-up of patients with relapse-onset of multiple sclerosisBrain2008131380881718234696
   PubMed Web of Science ®Google Scholar
• SimonJHKinkelRPKollmanCCHAMPIONS Investigators GroupTen-year follow-up of the “minimal MRI lesion” subgroup from the original CHAMPS multiple sclerosis prevention trialMult Scler201521441542225344370
   PubMed Web of Science ®Google Scholar
• TrappBDRansahoffRRudickRAAxonal pathology in multiple sclerosis: relationship to neurologic disability [review]Curr Opin Neurol199912329530210499174
   PubMed Web of Science ®Google Scholar
• European Medicine Agency (EMA)Product Information Tysabri2014 Available from: http://www.ema.europa.euAccessed December, 2014
   Google Scholar
• US Food and Drug Administration (FDA)Product Information Tysabri2014 Available from: http://www.FDA.govAccessed December, 2014
   Google Scholar
• PlavinaTSubramanyamMBloomgrenGAnti-JC-virus antibody levels in derum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathyAnn Neurol201476680281225273271
   PubMed Web of Science ®Google Scholar
• AntoniolCStankoffBImmunological markers for PML prediction in MS patients treated with natalizumabFront Immunol2015566825601865
   PubMed Web of Science ®Google Scholar
• CutterGRStüveODoes risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?Mult Scler201420101304130524812045
   PubMed Web of Science ®Google Scholar
• OlssonTAchironAAlfredssonLAnti-JC virus antibody prevalence in a multinational multiple sclerosis cohortMult Scler201319111533153823459571
   PubMed Web of Science ®Google Scholar
• LeePPlavinaTCastroAA second generation ELISA (STRATIFY JCVTM Dx Select TM) for detection of JC virus antibodies in human serum and plasma to support prorgessice multifocal leukoencephalopathy risk stratificationJ Clin Virol201357214114623465394
   PubMed Web of Science ®Google Scholar
• OutteryckOZéphirHSalleronJJC-virus seroconversion in multiple sclerosis patients receiving natalizumabMult Scler2014207822829
   Web of Science ®Google Scholar
• TurCMontalbanXNatalizumab: risk stratification of individual patients with multiple sclerosisCNS Drugs201428764164824942634
   PubMed Web of Science ®Google Scholar
• European Medicine Agency (EMA)Product Information Gilenya2015 Available from: http://www.ema.europa.euAccessed January 27, 2015
   Google Scholar
• US Food and Drug Administration (FDA)Product Information Gilenya2015 Available from: http://www.fda.govAccessed January 27, 2015
   Google Scholar
• KalincikTHorakovaDSpelmanTMSBase Study GroupSwitch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisAnn Neurol201577342543525546031
   PubMed Web of Science ®Google Scholar
• CarruthersRLRotsteinDLHealyBCChitnisTWeinerHLBuckleGJAn observational comparison of natalizumab versus fingolimod usind JCV serology to determine therapyMult Scler201420101381139024852928
   PubMed Web of Science ®Google Scholar
• RosenstielPVGottschalkRCappielloLZhangYSaidMKapposLLong-term safety of fingolimod: interim evaluation of data from the longterms trialMult Scler Relat Disord20143675225891590
   PubMedGoogle Scholar
• European Medicine Agency (EMA)Product Information Lemtrada2015 Available from: http://www.ema.europa.euAccessed January 27, 2015
   Google Scholar
• US Food and Drug Administration (FDA)Lemtrada (Alemtuzumab)2015 Available from: http://www.fda.orgAccessed March 31, 2015
   Google Scholar
• FilippiniGDel GiovaneCVacchiLImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCochrane Database Syst Rev20136CD00893323744561
   PubMed Web of Science ®Google Scholar
• CukerAColesAJSullivanHA distinctive form of immune thrombocytopenis in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosisBlood2011118246299630521960587
   PubMed Web of Science ®Google Scholar
• GormanMHealyBPolgar-TurcsanyiMChitnisTIncreased relapse-rate in pediatric-onset compared to adult-onset multiple sclerosisArch Neurol2009661545919139299
   PubMed Web of Science ®Google Scholar
• YehEAWaubantEKruppLBNetwork of Pediatric MS Centers of ExcellenceMultiple sclerosis therapies in pediatric patients with refractory diseaseArch Neurol201168443744421149803
   PubMedGoogle Scholar
• KornekBAboul-EneinFRostasyKNatalizumab therapy for highly active multiple sclerosisJAMA Neurol201370446947523420110
   PubMed Web of Science ®Google Scholar
• GhezziAPozzilliCGrimaldiLMItalian MS Study GroupNatalizumab in pediatric multiple sclerosis: results of a cohort of 55 casesMult Scler20131981106111223401129
   PubMed Web of Science ®Google Scholar
• TrampeAKHemmelmannCStroetAAnti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohortNeurology201278221736174222592369
   PubMed Web of Science ®Google Scholar
• MenzinJCaonCNicholsCWhiteLAFriedmanMPillMWNarrative review on the literature on adherence to disease-modifying therapies among patients with multiple sclerosisJ Manag Care Pharm2013101 suppl AS24S4023383731
   PubMed Web of Science ®Google Scholar
• HalpernRAgarwalSBortonLOneacreKLopez-BresnahanMVAdherence and persistence among multiple sclerosis patients after one immunomodulatory failure: retrospective claims analysisAdv Ther201128976177521870169
   PubMed Web of Science ®Google Scholar
• BergvallNPetrillaAAKarkareSUPersistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US database claims analysisJ Med Econ2014171069670725019581
   PubMedGoogle Scholar
• GlanzBIMusallamARintellDJTreatment satisfaction in multiple sclerosisInt J MS Care2014162687525061430
   PubMedGoogle Scholar
• BorrielloGProsperiniLMancinelliCGiannìCFubelliFPozzilliCPulse monthly steroids during an elective interruption of natalizumab: a post-marketing studyEur J Neurol201219578387822054236
   PubMed Web of Science ®Google Scholar
• WestTWCreeBANatalizumab dosage suspension: are we helping or hurting?Ann Neurol201068339539920818793
   PubMed Web of Science ®Google Scholar
• RossiSMottaCStuderVEffect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumabEur J Neurol2013201879422741530
   PubMed Web of Science ®Google Scholar
• StüveOCravensPDFrohmanEMImmunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNeurology200972539640118987352
   PubMed Web of Science ®Google Scholar
• FoxRJCreeBACDe SèzeJMS disease activity in RESTORE: a randomized 24-week natalizumab interruption studyNeurology201482171491149824682966
   PubMed Web of Science ®Google Scholar
• ClericoMSchiavettiIDe MercantiSFTreatment of relapsing remitting multiple sclerosis after 24 doses of natalizumab. Evidence from an Italian spontaneous, prospective, and observational study (TY-STOP Study)JAMA Neurol201471895496024977406
   PubMed Web of Science ®Google Scholar
• HavlaJTackenbergBHellwigKFingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJ Neurol201326051382138723266894
   PubMed Web of Science ®Google Scholar
• LaroniABrogiDMilesiVAbateLUccelliVMancardiGEarly switch to fingolimod may decrease the risk to disease recurrence after natalizumab interruptionMult Scler20131991236123723184503
   PubMed Web of Science ®Google Scholar
• CentonzeDRossiSRinaldiFGalloPSevere relapses under fingolimod treatment prescribed after natalizumabNeurology201279192004200523035063
   PubMed Web of Science ®Google Scholar
• SempereAPMartín-MedinaPBerenguer-RuizLSwitiching from natalizumab to fingolimod: an observational studyActa Neurol Scand2013128e6e1023336398
   PubMed Web of Science ®Google Scholar
• JokubaitisVGLiVKalincikTMSBase Study GroupFingolimod after natalizumab and the risk of short-term relapseNeurology2014821204121124610329
   PubMed Web of Science ®Google Scholar
• KapposLDisease control and safety in relapsing-remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32 week, rater- and patient blind, randomized, parallel-group study (TOFINGO)Mult Scler201319S150 Oral presentation 167
   Google Scholar
• GiovannoniGNaismithRTNatalizumab to fingolimod washout in patients at risk for PML: when good intentions yield bad outcomesNeurology201482141196119724610331
   PubMed Web of Science ®Google Scholar
• FDAFDA Drug Safety Communication: FDA Warns About Case of Rare Brain Infection PML with MS Drug Tecfidera2014 Available from: www.fda.gov/Drugs/DrugSafety/ucm424625.htmAccessed January 25, 2015
   Google Scholar
• ErmisUWiesmannMNolteKFumaric acid-associated progressive multifocal leukencephalopathy (PML), treatment and survival in a patient with psoriasisKongress der Deutschen Gesellschaft für Neurologie2011143040
   Google Scholar
• van OostenBWKilllesteinJBarkhofFPolmanCHWattjesMPPML in a patient treated with dimethyl fumarate from a compounding pharmacyN Engl J Med2013368171659166123614605
   PubMed Web of Science ®Google Scholar